Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Gsk save search
Lilly, Vir Biotechnology and GSK Announce First Patient Dosed in Expanded BLAZE-4 Trial Evaluating Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19
Published: 2021-01-27 (Crawled : 12:00) - globenewswire.com
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: -1.12%
H: 0.1%
C: -1.6%
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
|
| O: -0.78%
H: 0.45%
C: -1.66%
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: -7.13%
H: 96.21%
C: 15.59%
covid ev biotech trial
GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr
Published: 2022-09-22 (Crawled : 07:00) - biospace.com/
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: -0.71%
H: 2.03%
C: 1.52%
SPRO | $1.42 -1.05% -1.77% 110K
|
Health Technology
|
| O: 148.27%
H: 55.88%
C: 7.84%
license therapeutics agreement
Europe Frontotemporal Dementia Market Research Report 2023: Growing Prevalence of Dementia & Increasing Number of Clinical Trials - Competition, Forecasts & Opportunities to 2028
Published: 2023-04-26 (Crawled : 15:20) - prnewswire.com
GLAXF | News | $19.54 -3.77% -14.18% 170
|
Health Technology
|
| O: -4.57%
H: 0.22%
C: -1.98%
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: -1.46%
H: 0.0%
C: 0.0%
NVSEF | News | $96.0 0.94% 6.88% 0
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
VTRS | News A | $11.55 1.67% 1.65% 4.4M
|
Health Technology
|
| O: 0.22%
H: 0.65%
C: -1.09%
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: 0.62%
H: 0.0%
C: -2.04%
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: -0.66%
H: 0.18%
C: -0.9%
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: -0.03%
H: 0.3%
C: -2.63%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 0.53%
H: 0.0%
C: 0.0%
CNTG | $0.461 -3.96% -1.05% 20K
|
Commercial Services
|
| O: 1.23%
H: 27.27%
C: -15.76%
europe report dementia trials research growing market
Wave Life Sciences and GSK Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic Targets
Published: 2022-12-13 (Crawled : 13:20) - biospace.com/
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: 2.3%
H: 0.66%
C: -1.04%
WVE | $5.01 -1.38% -1.4% 430K
|
Health Technology
|
| O: 19.11%
H: 18.37%
C: 11.4%
sciences collaboration life genetic therapeutics
Fulcrum Therapeutics Announces Second Quarter 2022 Financial Results and Business Update
Published: 2022-08-11 (Crawled : 12:00) - biospace.com/
GLAXF | News | $19.54 -3.77% -14.18% 170
|
Health Technology
|
| O: -12.81%
H: 8.43%
C: 5.21%
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: -8.67%
H: 2.89%
C: 2.14%
FULC | $7.28 -2.15% -2.27% 350K
|
Health Technology
|
| O: -10.82%
H: 17.27%
C: 9.39%
therapeutics update results
Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19
Published: 2021-01-12 (Crawled : 08:03) - globenewswire.com
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: -0.29%
H: 0.21%
C: -0.95%
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: 1.91%
H: 16.28%
C: 11.28%
covid biotech treatment
SpringWorks Announces Expansion of Global, Non-Exclusive Collaboration with GSK for Nirogacestat in Combination with Blenrep in Patients with Multiple Myeloma
Published: 2022-09-07 (Crawled : 14:00) - globenewswire.com
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: -0.83%
H: 1.22%
C: 0.9%
SWTX | $43.38 -1.41% -1.45% 500K
|
Health Technology
|
| O: -0.38%
H: 15.79%
C: 7.56%
expansion collaboration
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
Published: 2023-04-11 (Crawled : 15:20) - biospace.com/
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: -0.11%
H: 0.0%
C: -1.27%
ADAP | $1.08 -5.26% -5.07% 790K
|
Health Technology
|
| O: -1.77%
H: 11.71%
C: 9.01%
transfer back
Anxious World Waits As Covid Vaccine Makers Address Omicron Variant
Published: 2021-12-07 (Crawled : 14:00) - prnewswire.com
GLAXF | News | $19.54 -3.77% -14.18% 170
|
Health Technology
|
| O: 5.22%
H: 0.0%
C: -1.25%
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: 2.13%
H: 0.0%
C: 0.0%
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: 0.14%
H: 0.0%
C: 0.0%
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: -6.42%
H: 8.6%
C: 8.45%
SRNE | $0.02 33.33% -8.85% 97K
|
Health Technology
|
| O: 6.57%
H: 14.77%
C: 11.21%
RDHL | $0.4199 -1.85% -3.08% 190K
|
Health Technology
|
| O: 0.37%
H: 10.37%
C: 9.63%
covid vaccine
Vir Biotechnology and GSK Provide Update on NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19
Published: 2021-03-03 (Crawled : 15:00) - biospace.com/
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: -0.26%
H: 0.93%
C: 0.71%
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: -28.99%
H: 8.39%
C: 1.9%
covid biotech iot trial
Anti-obesity Drugs Market Size to Grow by USD 454.51 million | Growing Obese Population to Boost Market Growth | 17,000+ Technavio Research Reports
Published: 2022-07-06 (Crawled : 15:00) - prnewswire.com
GLAXF | News | $19.54 -3.77% -14.18% 170
|
Health Technology
|
| O: -0.73%
H: 1.02%
C: 1.02%
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: -0.51%
H: 0.73%
C: 0.07%
BHC | $8.56 0.35% 0.12% 2M
|
Health Technology
|
| O: -0.77%
H: 1.61%
C: -4.45%
RYTM 4 | $39.71 -0.73% -0.73% 400K
|
Health Technology
|
| O: 0.45%
H: 8.37%
C: 7.24%
research growing growth market obesity
Zentalis Announces Preclinical Data Supporting Cyclin E1 As A Predictive Marker For Azenosertib Treatment At AACR Annual Meeting 2023
Published: 2023-04-17 (Crawled : 14:00) - biospace.com/
GLAXF | News | $19.54 -3.77% -14.18% 170
|
Health Technology
|
| O: 0.88%
H: 3.85%
C: 3.85%
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: -0.24%
H: 0.01%
C: -0.77%
ZNTL | $11.77 -6.36% -6.89% 850K
|
Health Technology
|
| O: 1.54%
H: 8.37%
C: 5.89%
treatment preclinical meeting
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
Published: 2022-03-17 (Crawled : 12:00) - biospace.com/
GLAXF | News | $19.54 -3.77% -14.18% 170
|
Health Technology
|
| O: -1.77%
H: 0.0%
C: -3.55%
CGEM | $18.89 13.32% 11.8% 1.2M
|
|
| O: -2.53%
H: 7.62%
C: 7.29%
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: 0.6%
H: 2.92%
C: 2.21%
financial results report results
New Data for AREXVY, GSK’s RSV Vaccine, Show Potential to Help Protect Adults Aged 50 to 59 at Increased Risk for RSV Disease
Published: 2023-10-25 (Crawled : 12:00) - biospace.com/
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: 0.42%
H: 0.43%
C: -0.22%
AGEN A | $7.42 14.86% 12.94% 1.2M
|
Health Technology
|
| O: -0.12%
H: 7.47%
C: 3.21%
disease risk rsv potential show
Cellular Immunotherapy Market Research Report by Type, Indication, Technology Type, End Use, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
Published: 2022-11-10 (Crawled : 17:00) - prnewswire.com
GLAXF | News | $19.54 -3.77% -14.18% 170
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
AZNCF | News | $135.35 -3.53% -4.19% 400
|
Health Technology
|
| O: 6.22%
H: 3.13%
C: -0.56%
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: 2.81%
H: 0.43%
C: -0.2%
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: 2.59%
H: 0.72%
C: 0.63%
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: 1.22%
H: 0.01%
C: -1.7%
IOVA 4 | $11.71 -1.27% -1.45% 2.9M
|
Health Technology
|
| O: 6.12%
H: 4.99%
C: 4.21%
INO | $10.16 -2.03% -2.67% 250K
|
Health Technology
|
| O: 5.5%
H: 4.35%
C: 3.48%
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: 1.43%
H: 0.36%
C: -1.08%
ATRA | $0.7147 -0.54% -1.2% 640K
|
Health Technology
|
| O: 2.58%
H: 23.12%
C: 20.85%
AZN | News | $71.2 0.49% 0.46% 5.4M
|
Health Technology
|
| O: 7.08%
H: 0.84%
C: -0.43%
ADAP | $1.08 -5.26% -5.07% 790K
|
Health Technology
|
| O: 0.0%
H: 7.14%
C: 5.71%
covid-19 research global immunotherapy report impact technology market
US FDA Approves GSK’s AREXVY, the World’s First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults
Published: 2023-05-03 (Crawled : 23:00) - biospace.com/
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: 1.24%
H: 1.14%
C: 0.11%
AGEN A | $7.42 14.86% 12.94% 1.2M
|
Health Technology
|
| O: 1.42%
H: 6.99%
C: 4.2%
fda vaccine respiratory virus
GSK Announces AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Is Now Available at All Major US Retail Pharmacies
Published: 2023-08-17 (Crawled : 18:00) - biospace.com/
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: -0.83%
H: 0.62%
C: 0.29%
AGEN A | $7.42 14.86% 12.94% 1.2M
|
Health Technology
|
| O: 0.0%
H: 6.35%
C: 4.76%
retail respiratory virus
Global Lupus Therapeutic Market to Surpass US$ 5,408.1 Million by 2030, Says Coherent Market Insights
Published: 2022-03-16 (Crawled : 18:00) - prnewswire.com
GLAXF | News | $19.54 -3.77% -14.18% 170
|
Health Technology
|
| O: -0.46%
H: 3.49%
C: 3.49%
NVSEF | News | $96.0 0.94% 6.88% 0
|
Health Technology
|
| O: 2.25%
H: 0.0%
C: 0.0%
UCBJY | $64.79 -0.72% -4.38% 3.4K
|
Manufacturing
|
| O: 1.41%
H: 2.33%
C: 0.04%
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 2.07%
H: 1.62%
C: 1.56%
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: 0.26%
H: 0.31%
C: -0.39%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 0.82%
H: 0.0%
C: 0.0%
AUPH | $5.03 -1.18% -1.19% 790K
|
Health Technology
|
| O: 0.95%
H: 6.23%
C: 5.19%
AMGN | News | $273.01 -0.19% -0.17% 1.5M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: -0.37%
lupus market
$12+ Billion Influenza Vaccines Market to Grow at 7+% CAGR, Globally, by 2028 Lead by Quadrivalent Vaccines Segment with 88.36% Market Share in 2022 | The Insight Partners
Published: 2022-10-28 (Crawled : 11:00) - prnewswire.com
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: 3.33%
H: 0.74%
C: -1.67%
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: 0.89%
H: 1.3%
C: 0.79%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 2.57%
H: 0.0%
C: 0.0%
MRNA | News S | $108.85 0.89% 0.85% 3M
|
Health Technology
|
| O: -0.88%
H: 5.85%
C: 5.69%
influenza market vaccine
ContraFect Appoints Gary Woodnutt, Ph.D. as Senior Vice President of Translational Sciences and Preclinical Development
Published: 2021-06-17 (Crawled : 12:00) - globenewswire.com
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: -0.47%
H: 0.44%
C: 0.25%
CFRX | $0.05 0.0% 910K
|
Health Technology
|
| O: 0.24%
H: 5.29%
C: -1.2%
preclinical pre-clinical
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.